Search
Nadifloxacin
go.drugbank.com/drugs/DB12447InvestigationalNadifloxacin has been used in trials studying the treatment of Acne Vulgaris.
Categories: Topoisomerase II InhibitorsMLN0415
go.drugbank.com/drugs/DB05183ExperimentalIn preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins. … MLN0415 is a novel, small molecule IKK2 inhibitor, discovered by Millennium scientists.
Proparacaine
go.drugbank.com/drugs/DB00807ApprovedVet approvedProparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
Banoxantrone
go.drugbank.com/drugs/DB04975InvestigationalBanoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours. … Banoxantrone was also efficacious in tumour models when administered in combination with either cisplatin or chemoradiation. [A3115]
Phenobarbital
go.drugbank.com/drugs/DB01174ApprovedInvestigationalA barbituric acid derivative that acts as a nonselective central nervous system depressant. … It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C18 Substrates with a Narrow Therapeutic Index10-hydroxycamptothecin
go.drugbank.com/drugs/DB12385Experimental10-hydroxycamptothecin is under investigation in clinical trial NCT00956787 (Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)).
Vesnarinone
go.drugbank.com/drugs/DB12082InvestigationalVesnarinone has been used in trials studying the treatment of HIV Infections and Sarcoma, Kaposi.
Categories: Compounds used in a research, industrial, or household settingNGX267
go.drugbank.com/drugs/DB05152InvestigationalNGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.
VLTS-589
go.drugbank.com/drugs/DB05430InvestigationalVLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.